Frontlight ResearchEarly access
CompletedPhase 3
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Key facts
- Who runs it
- Bioprojet
- Where
- Finland, France, Italy, Netherlands, and Russia9 sites in 5 countriesChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 110 people enrolled
- Started
- 6 Jun 2016
- Ended
- 5 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- pitolisant
- Placebo
- Record updated
- 26 June 2025
Who can take part
- Age
- 6 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male and female children from 6 to less than 18 years of age suffering from narcolepsy with or without cataplexy - ICSD-3 criteria (narcolepsy type 1 and 2)
- PDSS
- Patients should be free of non-authorized medication, in particular psychostimulant treatments as from the screening visit onwards
- Parents - and patients old enough to understand who have expressed a willingness to participate in the study, who have signed and dated the informed consent form prior to beginning protocol required procedures
- In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g., transportation to and from trial site, self rating scales and diaries completion, drug compliance, scheduled visits, tests)
Who cannot take part
- Any other conditions that can be considered the primary causes of EDS
- Psychiatric and neurological disorders in the investigator's opinion, would preclude the patient's participation and completion of this trial or comprise reliable representation of subjective symptoms
- Active clinically significant illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, haematological, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study objectives
- Any significant abnormality of the electrocardiogram and particularly Fridericia's QTc interval
- Patients with significant abnormality or clinical laboratory results
- Cataplectic patients treated by anticataplectics which are not under a stable treatment at the time of inclusion
- Patients treated for cataplexy or any other pathology, by tricyclic antidepressants
Where is this trial?
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this multicenter double blind study is to assess efficacy and safety of Pitolisant versus placebo in paediatric Narcoleptic patients with or without cataplexy.
The 2 groups in the trial
- pitolisantTreatment being tested
tablet, oral, once a day.
- placeboPlacebo, for comparison
tablet, oral, once a day.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period
- Publications
- Record updated
- 26 June 2025